• Description
  • Programmes
  • Contact

Sectors: Education - Training, Environment, Health, Innovation, New technologies, Research

Beneficiaries: Administrations States, Corporations, Development NGOs, Local and Regional authorities, Non-profit organisations, Research centres, Schools, SMEs, Universities

Regions: European Union, Worldwide

Category: Call for proposals


To view this information, please connect.

Responsible: European commission


The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

Priorities and funded actions:

– IMI2-2016-10-01: Understanding hypoglycaemia: the underlying mechanisms and addressing clinical determinants as well as consequences for people with diabetes by combining databases from clinical trials
– IMI2-2016-10-02: How Big Data could support better diagnosis and treatment outcomes for Prostate Cancer
– IMI2-2016-10-03: Improving the care of patients suffering from acute or chronic pain
– IMI2-2016-10-04: Creation of a pan-European Paediatric Clinical Trials Network
– IMI2-2016-10-05: Biomanufacturing 2020: Development of Innovative high throughput analytical tools and methods to characterize cell culture fluid during development and commercial cell culture processes
– IMI2-2016-10-06: Unlocking the Solute Carrier Gene-Family for Effective New Therapies (Unlock SLCs)
– IMI2-2016-10-07: Patient perspectives in medicines lifecycle
– IMI2-2016-10-08: Personalised medicine approaches in autism spectrum disorders

For more informations:
Click here